Skip to main content

Advertisement

SpringerLink
Log in

Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase

  • Chronic Myeloid Leukemias (J Pinilla-Ibarz, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

The introduction of tyrosine kinase inhibitors (TKIs) has fundamentally changed the management of chronic myeloid leukemia (CML). Disease progression to advanced phase (accelerated or blast phase) has been reduced to 1 to 1.5 % per year from more than 20 % per year in the pre-TKI era. However, once the disease has progressed to accelerated or blast phase, there is no consensus regarding optimal therapy. The prognosis of these patients is dismal with median survival ranging from 7 to 11 months. TKIs along with allogeneic hematopoietic cell transplantation are conventional strategies in managing these patients but there are very few long-term survivors. Advanced phase CML represents the new frontier for CML treatment where research is critically needed to improve patient outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Druker BJ et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–42.

    Article  CAS  PubMed  Google Scholar 

  2. Cortes J. Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:569–84.

    Article  PubMed  Google Scholar 

  3. Kantarjian H et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441–46.

    Article  CAS  PubMed  Google Scholar 

  4. Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol. 2003;40:79–86.

    Article  PubMed  Google Scholar 

  5. Howlader N et al. (eds). SEER Cancer Statistics Review, 1975–2012, National Cancer Institute. Bethesda, MD.

  6. Kantarjian H et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119(9):1981–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Druker BJ et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–17.

    Article  CAS  PubMed  Google Scholar 

  8. Saglio G et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251–59.

    Article  CAS  PubMed  Google Scholar 

  9. Kantarjian H et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260–70.

    Article  CAS  PubMed  Google Scholar 

  10. Radich JP, The biology of CML blast crisis. Hematol Am Soc Hematol Educ Program. 2007:384–91.

  11. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103(11):4010–22.

    Article  CAS  PubMed  Google Scholar 

  12. Lugo TG et al. Tyrosine kinase activity and transformation potency of the BCR-ABL oncogene products. Science. 1990;247:1079–82.

    Article  CAS  PubMed  Google Scholar 

  13. Cortes JE et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006;106(6):1306–15.

    Article  CAS  PubMed  Google Scholar 

  14. Vardiman JWMJ, Baccarani M, Thiele J. Chronic myelogenous leukemia BCR-ABL1 positive. In: Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopotietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.

    Google Scholar 

  15. Speck B et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet. 1984;8378(1):665–68.

    Article  Google Scholar 

  16. Baccarani M et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84. Updated recommendations of the European LeukemiaNet regarding the management of chronic myeloid leukemia, including accelerated and blast phases.

    Article  CAS  PubMed  Google Scholar 

  17. Kantarjian H et al. Survival benefit with imatinib mesylate therapy inpatients with accelerated-phase chronic myelogenous leukemia – comparison with historic experience. Cancer. 2005;103(10):2099–108.

  18. Jiang Q et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood. 2011;117(11):3032–40.

  19. Hoffmann VS et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia. 2013;27(10):2016–22.

  20. Furtado VF et al. Accelerated phase chronic myeloid leukemia: evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase. Rev Bras Hematol Hemoter. 2015;37(5):341-7.

  21. Kantarjian HM et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002;8(7):2167–76.

  22. Talpaz M et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99(6):1928–37.

    Article  CAS  PubMed  Google Scholar 

  23. Guilhot F et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109(10):4143–50.

    Article  CAS  PubMed  Google Scholar 

  24. Kantarjian H et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009;113(25):6322–9. 405.

  25. Apperley JF et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol. 2009;27(21):3472–9.

    Article  CAS  PubMed  Google Scholar 

  26. le Coutre PD et al. Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or in- tolerance: 24-month follow-up results. Leukemia. 2012;26(6):1189–94.

    Article  PubMed  Google Scholar 

  27. Kantarjian H et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542–51.

    Article  PubMed  Google Scholar 

  28. Nicolini FE et al. Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. Leuk Lymphoma. 2012;53(5):907–14.

    Article  CAS  PubMed  Google Scholar 

  29. Gambacorti-Passerini C et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015;90(9):755–68. This study established the long-term (>4 years of follow-up) efficacy and safety of bosutinib in accelerated phase CML patients refractory or resistant to prior treatment with imatinib, nilotinib, and dasatinib.

    Article  CAS  PubMed  Google Scholar 

  30. Cortes JE et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–96. This is a landmark study that demonstrated the efficacy of ponatinib as a salvage strategy in CML patients across all disease phases including accelerated phase CML with unmutated or mutated BCR-ABL who were refractory to nilotinib and dasatinib. Additionally, this study established ponatinib as the only TKI with activity in CML patients harboring T315I mutation.

    Article  CAS  PubMed  Google Scholar 

  31. Gratwohl A, Hermans J, Niederwieser D, Frassoni F, Arcese W, Gahrton G, et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Bone Marrow Transplant. 1993;12:509–16.

    CAS  PubMed  Google Scholar 

  32. McGlave P. Therapy of chronic myelogenous leukemia with related or unrelated donor bone marrow transplantation. Leukemia (Baltimore). 1992;6(Suppl):115–17.

    Google Scholar 

  33. Clift RA et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood. 1994;84:4368–73.

    CAS  PubMed  Google Scholar 

  34. Sacchi S et al. Chronic myelogenous leukemia in nonlymphoid blastic phase. Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86:2632–41.

    Article  CAS  PubMed  Google Scholar 

  35. Kantarjian H et al. Treatment of chronic myelogenous leukemia in accelerated and blastic phase with daunorubicin, high-dose cytarabine and granulocyte macrophage colony stimulating factor. J Clin Oncol. 1992;10:398–405.

    CAS  PubMed  Google Scholar 

  36. Kantarjian H et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-α and low-dose cytarabine. J Clin Oncol. 1992;10:772–78.

    CAS  PubMed  Google Scholar 

  37. Kantarjian H et al. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2000;18:3513–21.

    CAS  PubMed  Google Scholar 

  38. Giles FJ et al. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol. 2001;19:762–71.

    CAS  PubMed  Google Scholar 

  39. Silver RT et al. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukaemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica. 2009;94:743–44.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Kantarjian HM et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002;8(7):2167–76.

    CAS  PubMed  Google Scholar 

  41. Rea D et al. First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. Leukemia. 2012;26(10):2254–9.

    Article  CAS  PubMed  Google Scholar 

  42. Palandri F et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica. 2009;94(2):205–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Silver RT et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood. 2004;104:Abstract 23.

  44. Hochhaus A et al. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004;18:1321–31.

    Article  CAS  PubMed  Google Scholar 

  45. Ohanian M et al. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014;14(2):155–62 e1.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Khoury HJ, et al. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. Leuk Lymphoma. 2014.

  47. Radich JP et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am. 2004;18(3):685–702.

    Article  PubMed  Google Scholar 

  48. Giralt SA et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol. 2007;137(5):461–7.

    Article  CAS  PubMed  Google Scholar 

  49. O’Brien S et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw. 2009;7(9):984–1023.

    PubMed  Google Scholar 

  50. O’Brien S, Berman E, Moore JO, et al. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw. 2011;9 Suppl 2:S1–25.

    PubMed  PubMed Central  Google Scholar 

  51. Jabbour E et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011;117(13):3641–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Lee SJ et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008;112(8):3500–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Khoury HJ et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant. 2012;47(6):810–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Oehler VG et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2007;109(4):1782–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Breccia M et al. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leuk Res. 2010;34(2):143–7.

    Article  CAS  PubMed  Google Scholar 

  56. Latif AL et al. Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: a single centre’s experience. Leuk Res Rep. 2013;2(2):47–50.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, R35, 9500 Euclid Avenue, Cleveland, OH, 44195, USA

    Sudipto Mukherjee & Matt Kalaycio

Authors
  1. Sudipto Mukherjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matt Kalaycio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sudipto Mukherjee.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Chronic Myeloid Leukemias

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mukherjee, S., Kalaycio, M. Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase. Curr Hematol Malig Rep 11, 86–93 (2016). https://doi.org/10.1007/s11899-016-0304-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-016-0304-7

Keywords

Search

Navigation